Ultragenyx Pharmaceutical Inc. Stock News

Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the

While it's a common conspiracy theory – and comedic punchline – that medical innovators only seek to manage problems rather than cure them, the reality is that several biotech stocks to buy underg

NOVATO, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for se

Ultragenyx (RARE) reports a wider loss in the fourth quarter while revenues increase on growth in demand for its drugs.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q4 2022 Earnings Conference Call February 16, 2023 5:00 PM ET Company Participants Joshua Higa - Head of Investor Relations Emil Kakkis - Founder, Preside

Ultragenyx (RARE) delivered earnings and revenue surprises of -6.40% and 0.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx has been punished on the chart over the past 2 years to date. Investors haven't rewarded the company's top-line growth, nor recognized the potential in its investigational pathways.

NOVATO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri

Ultragenyx (RARE) reports preliminary product revenues for its marketed drugs, Crysvita, Mepsevii and Dojolvi for the full year 2022. The company issues product revenue guidance for 2023.

NOVATO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser

NOVATO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser

Ultragenyx Pharmaceutical Inc. has a number of approved products in a variety of rare diseases, and a solid pipeline. They are making over a quarter billion dollars every year (2021-22 figures).

Ultragenyx (RARE) reports a wider-than-expected loss in the third quarter. Revenues, though up year over year, miss estimates.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q3 2022 Earnings Conference Call November 2, 2022 5:00 PM ET Company Participants Joshua Higa - Head of Investor Relations Emil Kakkis - Founder, Presiden

Ultragenyx (RARE) delivered earnings and revenue surprises of -6.11% and 8.16%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?